Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,499,866
  • Shares Outstanding, K 61,574
  • Annual Sales, $ 203,200 K
  • Annual Income, $ -327,370 K
  • 60-Month Beta 1.66
  • Price/Sales 18.57
  • Price/Cash Flow N/A
  • Price/Book 1.62
Trade AGIO with:

Options Overview

Details
  • Implied Volatility 47.38%
  • Historical Volatility 35.79%
  • IV Percentile 2%
  • IV Rank 6.08%
  • IV High 95.90% on 11/02/20
  • IV Low 44.24% on 06/07/21
  • Put/Call Vol Ratio 0.50
  • Today's Volume 3,811
  • Volume Avg (30-Day) 615
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 9,677
  • Open Int (30-Day) 7,954

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -1.39
  • Number of Estimates 5
  • High Estimate -1.35
  • Low Estimate -1.45
  • Prior Year -1.31
  • Growth Rate Est. (year over year) -6.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.47 +1.69%
on 06/01/21
62.15 -9.24%
on 06/21/21
-0.70 (-1.23%)
since 05/21/21
3-Month
46.38 +21.63%
on 03/30/21
62.15 -9.24%
on 06/21/21
+5.35 (+10.48%)
since 03/23/21
52-Week
32.47 +73.73%
on 12/17/20
62.15 -9.24%
on 06/21/21
+4.54 (+8.75%)
since 06/23/20

Most Recent Stories

More News
Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat

Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.

RGEN : 192.92 (-2.15%)
TECH : 444.43 (+0.58%)
AGIO : 56.41 (-0.76%)
TRVN : 1.8900 (+0.53%)
Agios Launches myAgios(R) Patient Support Services for Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced the launch of...

AGIO : 56.41 (-0.76%)
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that it has submitted...

AGIO : 56.41 (-0.76%)
Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress

- Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 -

AGIO : 56.41 (-0.76%)
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and B-Thalassemia at the European Hematology Association Virtual Congress

- Study Met Primary Endpoint; Treatment with Mitapivat Induced Hemoglobin Increase of greater-than or equal to1.0 g/dL in 16 of 20 (80%) Patients During Weeks 4-12 -

AGIO : 56.41 (-0.76%)
Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress

- Agios to Host Investor Webcast on June 11 at 7:30 a.m. ET -

AGIO : 56.41 (-0.76%)
Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress

Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.

BMY : 65.26 (-1.03%)
AGIO : 56.41 (-0.76%)
NBRV : 1.3400 (-0.74%)
CDMO : 24.26 (+2.02%)
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -6.50% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?...

AGIO : 56.41 (-0.76%)
Agios Pharmaceuticals: Q1 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Thursday reported first-quarter net income of $1.87 billion, after reporting a loss in the same period a year earlier.

AGIO : 56.41 (-0.76%)
Agios Reports Business Highlights and First Quarter 2021 Financial Results

- Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency and Phase 2 Study of Mitapivat in Thalassemia Accepted for Presentation at EHA 2021 Virtual Congress...

AGIO : 56.41 (-0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It discovers and develops therapeutics in the field of cancer metabolism and inborn errors of metabolism. The Company's products include AG-221, AG-120, enzyme glutaminase and AG-348. Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts....

See More

Key Turning Points

3rd Resistance Point 58.53
2nd Resistance Point 57.81
1st Resistance Point 57.11
Last Price 56.41
1st Support Level 55.68
2nd Support Level 54.96
3rd Support Level 54.26

See More

52-Week High 62.15
Last Price 56.41
Fibonacci 61.8% 50.82
Fibonacci 50% 47.31
Fibonacci 38.2% 43.81
52-Week Low 32.47

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar